Dendritic cells in cancer immunotherapy clinical trials: are we making progress?
LH Butterfield - Frontiers in immunology, 2013 - frontiersin.org
Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two
decades. Over this time, the methods of DC culture (or manufacture) have evolved, the …
decades. Over this time, the methods of DC culture (or manufacture) have evolved, the …
Dendritic cell–based immunotherapy: state of the art and beyond
KF Bol, G Schreibelt, WR Gerritsen, IJM De Vries… - Clinical cancer …, 2016 - AACR
Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …
antitumor immune response against tumor antigens and was first explored in a clinical trial …
Dendritic cells in anticancer vaccination: rationale for ex vivo loading or in vivo targeting
AV Baldin, LV Savvateeva, AV Bazhin, AA Zamyatnin Jr - Cancers, 2020 - mdpi.com
Dendritic cells (DCs) have shown great potential as a component or target in the landscape
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …
Dendritic cells: a critical player in cancer therapy?
AK Palucka, H Ueno, J Fay… - Journal of …, 2008 - journals.lww.com
Cancer immunotherapy seeks to mobilize a patient's immune system for therapeutic benefit.
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …
It can be passive, that is, transfer of immune effector cells (T cells) or proteins (antibodies), or …
Dendritic-cell-based therapeutic vaccination against cancer
FO Nestle, A Farkas, C Conrad - Current opinion in immunology, 2005 - Elsevier
Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines,
tested different vaccine preparations, but they did not always induce sufficient acquired …
tested different vaccine preparations, but they did not always induce sufficient acquired …
Therapeutic Dendritic Cell− Based Cancer Vaccines: The State of the Art
MM Strioga, T Felzmann, DJ Powell Jr… - Critical Reviews™ in …, 2013 - dl.begellhouse.com
Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …
Dendritic cells: are they clinically relevant?
K Palucka, H Ueno, L Roberts, J Fay… - The Cancer …, 2010 - journals.lww.com
Cancer vaccines have undergone a renaissance because of recent clinical trials showing
promising immunologic data and some clinical benefit to patients. Current trials exploiting …
promising immunologic data and some clinical benefit to patients. Current trials exploiting …
Antitumor dendritic cell–based vaccines: lessons from 20 years of clinical trials and future perspectives
Dendritic cells (DCs) are versatile elements of the immune system and are best known for
their unparalleled ability to initiate and modulate adaptive immune responses. During the …
their unparalleled ability to initiate and modulate adaptive immune responses. During the …
Clinical application of dendritic cells in cancer vaccination therapy
IM Svane, ML Soot, S Buus, HE Johnsen - Apmis, 2003 - Wiley Online Library
During the last decade use of dendritic cells (DC) has moved from murine and in vitro
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …
Optimizing dendritic cell-based immunotherapy for cancer
H Zhong, MR Shurin, B Han - Expert review of vaccines, 2007 - Taylor & Francis
Dendritic cells (DCs) are the most powerful professional antigen-presenting cells and are
unique in their capability to initiate, maintain and regulate the intensity of primary immune …
unique in their capability to initiate, maintain and regulate the intensity of primary immune …